DNER and myelofibrosis: Several phase I and II clinical trials investigating BET inhibitors for its anti-proliferative effect in solid and hematologic malignancies are registered, and one phase III study is currently recruiting patients with myelofibrosis for the treatment with a BET inhibitor in combination with ruxolitinib, a janus kinase (JAK) inhibitor.